Meeting
2023 ASCO Annual Meeting
Dose escalation results from a first-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors.
Authors
Manish Sharma
START Midwest, Grand Rapids, MI
Manish Sharma , Yasutoshi Kuboki , D. Ross Camidge , Ruth Perets , David Sommerhalder , Noboru Yamamoto , Jair Bar , Apurvasena Parikh , Rui Li , Gladys Morrison Thiele , Martha Raluca Neagu Aristide , Kevin Jay Freise , John D. Powderly
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Chemotherapy and Antibody-Drug Conjugates
Clinical Trial Registration Number
NCT05029882
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3015)
DOI
10.1200/JCO.2023.41.16_suppl.3015
Abstract #
3015
Poster Bd #
213
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Characterization of diverse targetable ERBB2 alterations in 512,993 patients with solid tumors.
First Author: Dazhi Liu
Poster
2022 ASCO Annual Meeting
Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC).
First Author: Jonathan W. Goldman
Poster
2021 ASCO Annual Meeting
A single institution experience with droplet digital polymerase chain reaction (dd-PCR) liquid biopsy (LB) for therapeutic decision in advanced solid tumors.
First Author: Andre Marcio Murad
Poster
2020 ASCO Virtual Scientific Program
Therapeutic vulnerabilities among KRAS G12C mutant (mut) advanced cancers based on co-alteration (co-alt) patterns.
First Author: Maliha Nusrat